Only 30% of patients with GBM harbor the EGFRvIII mutation, but fortunately, EphA2 and IL13Ra2 are not expressed in normal brain tissue, making it sufficient to target a CNS-specific and not necessarily a tumor-specific antigen. Here, EPHA2 is linked to neoplasm.